
    
      A total of 60 patients who meet the criteria for admission and have a clinical diagnosis of
      hypercholesterolemia and have received statin for at least 4 weeks will be randomized and
      receive different dose groups of IBI306 or matching placebo. Ascending dose design includes 6
      dose levels: 75 mg Q2W, 140 mgQ2W, 300 mg Q4W，420mg Q4W, 450 mg Q6W，and 600 mg Q6W. Total
      duration of the study per subject is 12 weeks.
    
  